Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

INTRODUCTION: The cognitive safety of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has been established in clinical trials, but not yet in real-world observational studies. We assessed the cognitive function in patients initiating PCSK9i, and differences in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Seijas-Amigo, Jose, Mauriz-Montero, Mª José, Suarez-Artime, Pedro, Gayoso-Rey, Mónica, Estany-Gestal, Ana, Casas-Martínez, Antonia, González-Freire, Lara, Rodriguez-Vazquez, Ana, Pérez-Rodriguez, Natalia, Villaverde-Piñeiro, Laura, Castro-Rubinos, Concepción, Espino-Faisán, Esther, Rodríguez-Mañero, Moisés, Cordero, Alberto, González-Juanatey, José R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462529/
https://www.ncbi.nlm.nih.gov/pubmed/37612529
http://dx.doi.org/10.1007/s40256-023-00604-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462529/
https://www.ncbi.nlm.nih.gov/pubmed/37612529
http://dx.doi.org/10.1007/s40256-023-00604-6

Ejemplares similares